Senseonics Achieves Record Revenue in 2025, Looks Forward to New Developments in 2026
"We closed a successful 2025 on a high note, achieving by far our highest revenue quarter as our DTC efforts continue to drive an increasing number of patients to the world's first and only year-long CGM, said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. "We now look ahead to a 2026 that should bring more exciting developments for Senseonics, most notably the transition of commercial and distribution rights to Eversense 365 from Ascensia, which we expect will lead to higher revenue and improved gross margins. We also expect a boost from an anticipated CE mark in Europe for Eversense 365, the launch of the twiist system with full Eversense compatibility, and the completion of the Gemini trial in the second half of 2026. Taken together, we look forward to building on the momentum we established in 2025 to drive increased shareholder value in 2026 and beyond."
Get Free Real-Time Notifications for Any Stock
Analyst Views on SENS
About SENS
About the author

Strong Performance of European High Growth Tech Companies, Genmab Reports $3.85 Billion Revenue
- Market Resilience: The pan-European STOXX Europe 600 Index rose by 0.77%, supported by strong economic data and earnings results, indicating a cautious optimism in the market despite mixed performances among major stock indexes.
- Genmab's Innovative Partnership: Genmab's strategic alliance with Anthropic aims to integrate AI into its R&D processes, enhancing the efficiency of its antibody product clinical developments, which is expected to solidify its leading position in oncology.
- LINK Mobility's Recovery Potential: Despite a 40.4% contraction in earnings growth, LINK Mobility Group Holding is projected to achieve an annual earnings growth of 71.1%, significantly surpassing the Norwegian market's expectation of 15%, highlighting its strong recovery potential.
- Sensirion's Technological Leadership: Sensirion Holding AG excels in sensor technology with a 5.9% annual revenue growth and a forecasted 25.8% earnings growth, with innovations in environmental monitoring technology further enhancing its market competitiveness.

Senseonics (SENS) Reports Q4 2025 Revenue of ~$14.2M with 103% New Patient Growth
- Significant Revenue Growth: Senseonics reported preliminary unaudited Q4 2025 revenue of approximately $14.2 million and annual revenue of about $35.2 million, indicating strong market performance, with expectations for 2026 global net revenue to reach $58-$62 million, reflecting a growth of 65% to 76%.
- Innovative Patient Growth: The company achieved a remarkable 103% new patient growth in the U.S. during Q4, marking the largest addition of new patients in its history, primarily driven by effective direct-to-consumer marketing strategies, showcasing the effectiveness of its promotional efforts and enhanced brand influence.
- Gross Margin Expectations: Senseonics anticipates a gross margin of approximately 50% for 2026, which will further enhance its profitability and provide funding support for future investments and expansions, reflecting success in cost control and product pricing strategies.
- Enhanced Financial Transparency: The company plans to release its Q4 and full-year 2025 financial results on March 2, 2026, which will provide more financial details and bolster investor confidence in the company's future development, while also expecting a cash and cash equivalents balance of about $94.3 million as of December 31, 2025.









